| 孟玲楠 石砂硼 林珊 高纯子 韩波.不同放化疗模式治疗中晚期非小细胞肺癌的疗效分析[J].现代生物医学进展英文版,2016,16(29):5658-5662. |
| 不同放化疗模式治疗中晚期非小细胞肺癌的疗效分析 |
| The Analyses of Curative Effect of Different Chemo-radiotherapy Modes in the Treatment of Advanced Non-small Cell Lung Cancer |
| |
| DOI： |
| 中文关键词: 非小细胞肺癌 同步放化疗 序贯放化疗 |
| 英文关键词: Non-small cell lung cancer Concurrent radio-chemotherapy Sequential radio-chemotherapy |
| 基金项目:黑龙江省卫生厅科研课题（2012-547） |
|
| Hits: 858 |
| Download times: 0 |
| 中文摘要: |
| 目的：探讨同步和序贯放疗联合不同化疗方案对治疗中晚期非小细胞肺癌近期疗效、远期生存及毒性反应的影响。方法：将
45 例III-IV 期非小细胞肺癌患者随机归入两组，同步放化疗组22 例；序贯放化疗组23 例。全组病例依据病情分别选择艾素和顺
铂、吉西他滨和顺铂、长春瑞滨和顺铂或培美曲塞和顺铂方案化疗。比较两组近期疗效、远期生存率及毒性反应。结果：同步组近
期有效率为81.8%高于序贯组73.9%,但无统计学差异（P>0.05）；两组均有随放疗剂量增加有效率升高趋势。NP 和TP方案两组近
期疗效相近(P>0.05)。同步组和序贯组1 年生存率分别为90.9%和86.9%（P<0.05）；2 年生存率分别为72.7%和52.2%（P>0.05）。毒
性反应主要为骨髓抑制、放射性食管炎和肺炎。同步组毒副反应发生率高于序贯组，但无统计学差异(P>0.05)。结论：同步放化疗
治疗中晚期非小细胞肺癌近期疗效及远期生存率有优于序贯放化疗的趋势，但毒副反应发生相对增多。联合治疗模式下，分期越
早，患者远期生存时间越长。近期疗效有随放疗剂量增高而提高趋势，但放疗剂量、病理类型、化疗方案等对患者远期生存无明显
统计学差异。 |
| 英文摘要: |
| Objective:To explore the effect of short-term efficacy, the long-term survival rate and the toxicity in the treatment of
advanced non-small cell lung cancer with different chemotherapy regimens combined with concurrent radio-chemotherapy and sequential
radio-chemotherapy.Methods:45 patients of non-small cell lung cancer were randomized into two groups, which included 22 cases receiving
concurrent radio-chemotherapy and 23 cases receiving sequential radio-chemotherapy. All patients were given chemotherapy
with Vinorelbine and Cisplatin(NP), Gemcitabine and Cisplatin(GP), Taxotere and Cisplatin(TP) or Pemetrexed disodium and Cisplatin
(PP) regimens. Short-term efficacy, the long-term survival rate and the toxicity were compared between two groups.Results:The effective
rate of the concurrent radio-chemotherapy group (81.8% ) was higher than that of the sequential radio-chemotherapy group (73.9%)
(P>0.05). The effective rates were improved with the radiotherapy dose increasing in both groups. The NP and TP regimens have the similar
effective rates (P>0.05). The 1 year survival rate in the concurrent radio-chemotherapy group and sequential radio-chemotherapy
group were 90.9%and 86.9%(P<0.05), and 2 year survival rate were 72.7%and 52.2%(P>0.05). The toxicity in both groups were myelosuppression,
radiation esophagitis and radiation pneumonitis. And the concurrent radio-chemotherapy group was higher than sequential
radio-chemotherapy group(P>0.05).Conclusion:In the treatment of advanced non-small cell lung cancer, concurrent radio-chemotherapy
maybe better than sequential radio-chemotherapy, but the toxicity was significantly increased. The long-term survival rate was positively
correlated with the stage. The effective rates were improved with the radiotherapy dose, but the radiotherapy dose, pathological
type, chemotherapy regimens and so on had no significant differences to the long-termsurvival rate of the patients. |
|
View Full Text
View/Add Comment Download reader |
| Close |
